Skip to main content
Meeting Highlights
ASH Highlights, Leukemia
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL
Read More
Meeting Highlights
ASH Highlights, Leukemia
Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia
Read More
Meeting Highlights
ASH Highlights, Leukemia
All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy
Read More
Meeting Highlights
ASH Highlights, Lymphoma
Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma
Read More
Meeting Highlights
ASH Highlights, Immunotherapy, Lymphoma
Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma
Read More
Meeting Highlights
ASH Highlights, Myelofibrosis
Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis
Read More
Meeting Highlights
ASH Highlights, CAR T-Cell Therapy, Multiple Myeloma
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma
Read More
Meeting Highlights
ASH Highlights, CAR T-Cell Therapy, Multiple Myeloma
Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma
Read More
Meeting Highlights
ESMO Highlights
Ceritinib Effective in Treating Brain Metastases in NSCLC
Phoebe Starr
Read More
Meeting Highlights
ESMO Highlights, PARP Inhibitors
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer
Phoebe Starr
Read More
Page 143 of 199
Results 1421 - 1430 of 1986